COMy 2024 - The 10th World Congress on Controversies in Multiple Myeloma
May 23 - May 26, 2024 | ParisFrance
LARVOL is not affiliated with The 10th World Congress on Controversies in Multiple Myeloma and all trademarks, logos, and brand names are property of their respective owners
Showing 3 titles linked to Trials
EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): FINAL ANALYSIS OF THE PHASE 2 CENTAURUS STUDY
PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)
UPDATED RESULTS OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO T-CELL REDIRECTING THERAPIES: RESULTS OF THE PHASE 1/2 MONUMENTAL-1 STUDY